Cancer Research and Treatment

Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis

Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng

International Immunopharmacology.2023; 114: 109490. CrossRef

Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis

Su Jeong Song, Yun-Kyoung Song, Mihwa Jang, Eunjeong Shin, Sung Yun Suh, Yoon Sook Cho, Ju-Yeun Lee, Jung Mi Oh

Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis

Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo, Jing Min Cheng

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. K. Mok, Martin Reck, Gene G. Finley, Monika D. Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard J. West

Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment

Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfons

Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis

Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation

Sara Sheikhbahaei, Charles V. Marcus, Mohammad S. Sadaghiani, Steven P. Rowe, Martin G. Pomper, Lilja B. Solnes

American Journal of Roentgenology.2022; 218(6): 940. CrossRef

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain

The Journal of Clinical Pharmacology.2022; 62(4): 532. CrossRef

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harri

Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity

Ka Man Cheung, Therese Yue Man Tsui, James Chung Hang Chow

CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma

Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika

Journal of Personalized Medicine.2022; 12(6): 888. CrossRef

A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer

Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi

Cancer Research and Treatment.2022; 54(4): 1005. CrossRef

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences

Safety of sequential immune checkpoint inhibitors after prior immune therapy

Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu

Journal of Cancer Research and Clinical Oncology.2022;[Epub] CrossRef

Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy

Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray

European Journal of Cancer.2022; 172: 98. CrossRef

Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma

Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling

Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer

Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, Jerzy Chudek

The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex

Murielle N. Wahli, Stefanie Hayoz, Dennis Hoch, Christoph O. Ryser, Michèle Hoffmann, Amina Scherz, Birgit Schwacha-Eipper, Simon Häfliger, Julian Wampfler, Martin D. Berger, Urban Novak, Berna C. Özdemir

Journal of Cancer Research and Clinical Oncology.2022;[Epub] CrossRef

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence

Nari Kim, Eun Sung Lee, Sang Eun Won, Mihyun Yang, Amy Junghyun Lee, Youngbin Shin, Yousun Ko, Junhee Pyo, Hyo Jung Park, Kyung Won Kim

Korean Journal of Radiology.2022; 23(11): 1089. CrossRef

Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data

Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon

Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy

Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi

Journal of Cancer Research and Clinical Oncology.2022;[Epub] CrossRef

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity

Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles

The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mus

Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer

Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain

Clinical Cancer Research.2021; 27(10): 2706. CrossRef

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma

Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose

Gynecologic Oncology Reports.2021; 37: 100840. CrossRef

Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy

Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang

Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3639. CrossRef

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC

Jay M. Lee, Anthony W. Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Yi-Long Wu, Shawn W. Sun, Barbara J. Gitlitz

JTO Clinical and Research Reports.2021; 2(10): 100221. CrossRef

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael

Journal of Clinical Oncology.2021; 39(36): 4073. CrossRef

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu